Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma
Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma
批准号:
10446186
负责人:
Guang Peng
金额:
$38.65万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-08-16 至 2027-07-31
关键词:
ARID1A geneAnimal ModelBiochemistryBioinformaticsBiologyCRISPR/Cas technologyCellsCellular biologyChromatin Remodeling FactorCytosineDNADNA DamageDNA MethylationDNA RepairDNA SequenceDataDouble-Stranded RNAElementsFrequenciesGene SilencingGenesGeneticGenetic TranscriptionGenetic studyGoalsHeterochromatinImmuneImmunotherapyImpairmentInnate Immune ResponseInterferonsIonizing radiationMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMolecularMutateMutationNucleic AcidsOvarian CarcinomaOvarian Clear Cell TumorPathway interactionsPatientsPhosphorylationPhosphotransferasesProteomicsRNARadiationRadiation Induced DNA DamageRadiation exposureRadiation therapyRadiosensitizationRegimenRepressionResearchRoleSWI/SNF Family ComplexSamplingSatellite DNASerineSignal TransductionSiteStimulator of Interferon GenesTestingTherapeuticTransferaseTranslatingTumor Immunitybasecancer cellcancer genomicsclinical applicationeffective therapygenomic dataheterochromatin-specific nonhistone chromosomal protein HP-1improvedin vivoinhibitorinnate immune sensinginnovationinterdisciplinary approachnovel therapeuticsovarian neoplasmpre-clinicalprogramsradiation resistancerecruitresponsesmall hairpin RNAtherapeutically effectivetranslational studytumor
中文摘要
描述
卵巢透明细胞癌(OCCC)是卵巢癌中第二常见的类型,与
由于缺乏有效的治疗选择,存活率很低。我们的长期目标是了解
在OCCC中创造治疗机会并将这些发现转化为
有意义的临床应用。
ARID1A是染色质重塑复合体SWI/SNF的一种成分,在超过50%的OCCC中发生突变。
在我们目前的R01项目的支持下,我们已经建立了一个成功的研究计划来研究
ARID1A-SWI/SNF复合体在调节DNA损伤反应(DDR)和DNA修复中的作用在
在导致此次续签申请的初步研究中,我们发现了ARID1A-SWI/SNF的新角色
异染色质重复DNA序列转录沉默的复合体,即卫星DNA
元件(SatDNA)对电离辐射(IR)引起的DNA损伤的反应。我们还证明了这种反常
IR诱导的SatRNA表达激活ARID1A缺陷细胞的RNA感知先天免疫反应。
这些令人兴奋和有希望的发现使我们假设ARID1A缺乏释放IR-
通过破坏DNMT3A介导的DNA诱导异染色质重复SATDNA序列的降阻
甲基化和转录沉默。这因此激活了dsRNA传感RIG-1/MDA5
途径,并提供了使用ATM抑制剂来提高放射治疗和
选择性调节核酸介导的ARID1A缺陷先天免疫反应的免疫治疗
肿瘤。我们将采用多学科方法,包括以分子/生物化学/细胞生物学为基础
机制研究、基于shRNA/CRISPR-Cas9的遗传学研究、生物信息学分析和临床前研究
基于动物模型的翻译研究,以及对OCCC患者样本的分析来验证这一假设。
综上所述,我们提议的项目不仅将机械地推进我们对
ARID1A-SWI/SNF染色质重塑复合体维持异染色质的基础生物学
转录沉默对辐射诱导的DNA损伤,但也将发展新的个性化免疫-
根据肿瘤的遗传背景量身定做的放射治疗方案,如ARID1A缺乏或更多
广泛地说,SWI/SNF突变的癌症。
英文摘要
DESCRIPTION
Ovarian clear-cell carcinoma (OCCC) is the second most common type of ovarian cancer and is associated
with poor survival because of the lack of effective therapeutic options. Our long-term goal is to understand the
molecular mechanisms that create therapeutic opportunities in OCCC and to translate such discoveries into
meaningful clinical applications.
ARID1A, a component of the chromatin remodeling complex SWI/SNF, is mutated in more than 50% of OCCC.
With the support of our current R01 project, we have established a successful research program to study the
role of the ARID1A-SWI/SNF complex in regulating the DNA damage response (DDR) and DNA repair. In the
preliminary studies leading to this renewal application, we discovered a new role for the ARID1A-SWI/SNF
complex in transcriptional silencing of heterochromatin repetitive DNA sequences, namely satellite DNA
element (satDNA) in response to ionizing radiation (IR)-induced DNA damage. We also showed that aberrant
IR-induced satRNA expression activates RNA-sensing innate immune response in ARID1A-deficient cells.
These exciting and promising findings have led us to hypothesize that ARID1A deficiency unleashes IR-
induced de-repression of heterochromatin repetitive satDNA sequences by impairing DNMT3A-mediated DNA
methylation and transcriptional silencing. This consequently activates the dsRNA-sensing RIG-1/MDA5
pathway, and provides the rationale to use ATM inhibitors to enhance the efficacy of radiotherapy and
immunotherapy by selectively modulating nucleic acid-mediated innate immune response in ARID1A-deficient
tumors. We will employ multidisciplinary approaches, including molecular/biochemistry/cell biology-based
mechanistic studies, shRNA/CRISPR-Cas9-based genetic studies, bioinformatic analysis and preclinical
animal model-based translational studies, and analysis of OCCC patient samples to test this hypothesis.
Together, our proposed project will not only mechanistically advance our fundamental understanding of the
underlying biology of how the ARID1A-SWI/SNF chromatin remodeling complex maintains heterochromatin
transcriptional silencing to radiation-induced DNA damage, but will also develop new personalized immune-
based radiotherapy regimens tailored to the genetic contexts of tumors, such as ARID1A deficiency or more
broadly SWI/SNF-mutated cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of radioresistance and strategies for radiosensitization in OCCC
-
批准号:10218064
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2016
-
负责人:Guang Peng
-
依托单位:
Mechanisms of radioresistance and strategies for radiosensitization in OCCC
-
批准号:9564069
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2016
-
负责人:Guang Peng
-
依托单位:
Mechanisms of radioresistance and strategies for radiosensitization in OCCC
-
批准号:9763331
-
项目类别:
-
资助金额:$35.48万
-
财政年份:2016
-
负责人:Guang Peng
-
依托单位:
Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma
-
批准号:10684787
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Guang Peng
-
依托单位:
Understanding and Targeting the DNA Repair Network in Cancer
-
批准号:8795698
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2011
-
负责人:Guang Peng
-
依托单位:
Understanding and Targeting the DNA Repair Network in Cancer
-
批准号:8046568
-
项目类别:
-
资助金额:$8.75万
-
财政年份:2011
-
负责人:Guang Peng
-
依托单位:
Understanding and Targeting the DNA Repair Network in Cancer
-
批准号:8587577
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2011
-
负责人:Guang Peng
-
依托单位:
Understanding and Targeting the DNA Repair Network in Cancer
-
批准号:8303240
-
项目类别:
-
资助金额:$8.53万
-
财政年份:2011
-
负责人:Guang Peng
-
依托单位:
Understanding and Targeting the DNA Repair Network in Cancer
-
批准号:8618778
-
项目类别:
-
资助金额:$20.01万
-
财政年份:2011
-
负责人:Guang Peng
-
依托单位:
海外基金